Report

Opioid-induced Constipation Epidemiology Forecast 2025-2034
Opioid-induced constipation (OIC) affects a significant portion of patients receiving opioids, with estimates ranging from 40% to 60% in those without cancer. To prevent the condition, it is recommended that laxatives be started at the same time as opioid therapy.

Opioid-induced Constipation Epidemiology Forecast Report Coverage
The Opioid-induced Constipation Epidemiology Forecast Report 2025-2034 by Expert Market Research delivers a comprehensive analysis of the condition's prevalence and associated demographic factors. It projects future incidence and prevalence trends across diverse population groups, considering key variables such as age, gender, and opioid-induced constipation type. The report highlights change in prevalence over time and offers data-driven forecasts based on influencing factors. Additionally, it provides an in-depth overview of the disease, along with historical and projected epidemiological data for eight key markets: the United States, United Kingdom, France, Italy, Spain, Germany, Japan, and India.

Opioid-induced Constipation: Disease Overview
Opioid-induced constipation (OIC) is a common side effect of opioid use, affecting individuals who take these medications for pain management. It occurs due to the opioids' effects on the gastrointestinal system, slowing down motility and increasing fluid absorption, which leads to harder stools and difficulty passing them. Symptoms include abdominal discomfort, bloating, and infrequent bowel movements. The condition is particularly prevalent in patients with chronic pain. Treatment includes lifestyle changes, laxatives, and sometimes medications specifically designed to counteract opioid-induced constipation. Preventing OIC requires proactive management when starting opioid therapy.

Epidemiology Overview
The opioid-induced constipation epidemiology section provides insights into the patient pool, examining historical data and current trends, along with future projections across the 8 major markets. Expert Market Research presents both present and future trends by analyzing a broad range of studies. The report also details the diagnosed patient pool and their trends, categorising data by age groups and patient pools.
- Studies estimate that between 40% and 60% of non-cancer patients on opioid medication experience opioid-induced constipation.
- The global prevalence of opioid-induced constipation varies significantly, ranging from 8.9% to 81.0%, based on international research.
- A 2021 study in the International Journal of Clinical Oncology involving 50 Japanese patients with gastrointestinal cancer found that opioid-induced constipation affected 46.0% to 62.0% of patients, depending on diagnostic criteria.
- Additionally, research indicates that between 40% and 80% of individuals undergoing long-term opioid therapy will develop opioid-induced constipation.

Opioid-induced Constipation: Treatment Overview
Opioid-Induced Constipation (OIC) is a common adverse effect of opioid therapy, arising from reduced gastrointestinal motility. Unlike typical constipation, opioid-Induced constipation persists without tolerance over time. Effective management often combines lifestyle changes, pharmacologic agents, and preventive strategies. Treatment typically starts with over-the-counter laxatives, and if ineffective, progresses to targeted medications like peripherally acting mu-opioid receptor antagonists (PAMORAs). Customised care is essential to improve patients' comfort and adherence to opioid regimens, especially in those requiring long-term pain management.

1. Stimulant Laxatives
Stimulant laxatives such as senna or bisacodyl are commonly used to treat opioid-induced constipation. They work by stimulating the intestinal muscles, promoting bowel movements. These medications are typically used when fibre supplements or stool softeners are insufficient. While effective for short-term relief, long-term use may lead to dependency or bowel habituation. Stimulant laxatives are often recommended in conjunction with stool softeners for optimal benefit in opioid-induced constipation management, especially when the condition is mild to moderate.

2. Osmotic Laxatives
Osmotic agents, including polyethylene glycol (PEG), lactulose, or magnesium hydroxide, draw water into the intestines to soften stools and stimulate bowel movements. They are useful in treating opioid-induced constipation when stimulant laxatives are not effective or tolerated. PEG is commonly preferred for its efficacy and minimal systemic absorption. Osmotic laxatives are generally safe for long-term use but may cause bloating, gas, or diarrhoea. They are often the first-line pharmacologic option in OIC if non-drug approaches do not provide relief.

3. Peripherally Acting Mu-Opioid Receptor Antagonists (PAMORAs)
PAMORAs, such as methylnaltrexone, naloxegol, and naldemedine, are specifically designed for Opioid-Induced Constipation. These agents block opioid receptors in the gastrointestinal tract without affecting pain relief in the central nervous system. PAMORAs are effective in patients who do not respond to traditional laxatives. They offer targeted action with fewer systemic side effects. While generally well tolerated, they may cause abdominal pain or diarrhoea. PAMORAs are particularly valuable in moderate to severe OIC cases where conventional treatments fail.

4. Stool Softeners
Stool softeners like docusate sodium work by increasing water and fat absorption in the stool, making it easier to pass. They are often combined with stimulant laxatives for enhanced effect in opioid-induced constipation. While not as effective alone for opioid-related constipation, stool softeners are useful as part of a multi-modal approach, particularly for patients needing a gentler treatment option. These agents are well tolerated, but prolonged use without effect should prompt evaluation for stronger interventions like PAMORAs.

5. Lubiprostone
Lubiprostone is a chloride channel activator that enhances intestinal fluid secretion, promoting bowel movement. Approved for opioid-induced constipation in adults with chronic non-cancer pain, it is taken orally and can provide relief when conventional laxatives are inadequate. Lubiprostone does not interfere with the pain-relieving effects of opioids. Side effects may include nausea or diarrhoea. It is generally reserved for cases where first-line therapies fail or are poorly tolerated, offering a targeted and effective solution in the OIC treatment spectrum.

Opioid-induced Constipation: Burden Analysis
Opioid-Induced Constipation (OIC) poses a substantial burden on individuals requiring long-term opioid therapy. Unlike typical constipation, Opioid-induced constipation persists throughout opioid use, significantly impairing daily functioning, emotional well-being, and overall quality of life. Patients often report discomfort, bloating, and reduced appetite, leading to decreased adherence to pain management regimens. The condition can cause distress, anxiety, and social withdrawal due to the chronic nature of symptoms. Inadequate relief from conventional laxatives further intensifies patient dissatisfaction. OIC not only affects physical health but also adds to the economic burden through increased healthcare visits, reduced productivity, and reliance on costly prescription treatments.

Key Epidemiology Trends
Opioid-induced constipation is increasingly recognised as a significant public health concern, particularly as global opioid use for pain management continues to rise. Its epidemiological profile is shaped by evolving prescribing patterns, demographic shifts, and healthcare practices.

1. Rising Prevalence with Chronic Opioid Therapy
A notable trend is the increasing prevalence of opioid-induced constipation in patients undergoing long-term opioid treatment for both cancer-related and non-cancer-related pain. As opioid prescriptions grow, especially in ageing populations, more individuals are experiencing persistent gastrointestinal side effects. This pattern reflects the chronic nature of the condition, which often does not respond well to standard laxatives. As opioid use extends over longer durations, the associated constipation becomes a consistent and burdensome issue, especially among those with limited mobility or additional health complications.

2. Greater Awareness and Diagnosis
Improved awareness among healthcare providers and patients has led to increased diagnosis rates of opioid-induced constipation. Previously underreported or misclassified as general constipation, the condition is now more distinctly recognised due to specific diagnostic criteria and clinical tools. Medical guidelines now encourage early identification and management of opioid-induced constipation, leading to a more accurate epidemiological picture. Additionally, patient-reported outcome measures have improved the ability to capture symptom severity and treatment outcomes, enhancing the overall understanding of its burden.

3. Variability Across Regions and Populations
The epidemiology of opioid-induced constipation varies significantly by country and healthcare system. In regions where opioid prescribing is more liberal, particularly in developed nations, the incidence is markedly higher. Conversely, in countries with restricted opioid access, cases are less frequently observed. Socioeconomic factors, cultural attitudes towards opioid use, and healthcare infrastructure influence how commonly the condition is diagnosed and treated. Among specific populations, such as elderly adults or those with advanced cancer, prevalence rates are notably elevated due to increased opioid dependency and physiological susceptibility.

4. Gender and Age Disparities
Emerging data suggest gender-based and age-related differences in the incidence and reporting of opioid-induced constipation. Older adults are more vulnerable due to slower gastrointestinal motility and higher opioid use for chronic conditions. Women may report symptoms more frequently, possibly due to hormonal influences and differences in gut sensitivity. These disparities influence not only the epidemiological data but also necessitate targeted treatment approaches tailored to demographic profiles. Researchers are now exploring the underlying mechanisms behind these variations to develop more effective interventions.

5. Impact of Multimodal Pain Management
The shift toward multimodal pain management strategies, which combine opioids with non-opioid analgesics and non-pharmacological therapies, has begun to influence the epidemiology of opioid-induced constipation. This approach can reduce overall opioid dosage and, consequently, the risk of developing gastrointestinal side effects. Although still evolving, such trends suggest a potential plateau or decline in incidence in some clinical settings. The adoption of opioid-sparing protocols may reshape future epidemiological patterns by limiting the duration and intensity of opioid exposure, particularly in postoperative and chronic pain cases.

Analysis By Region
The epidemiology of opioid-induced constipation varies across countries and regions due to differences in healthcare infrastructure, socioeconomic factors, cultural attitudes towards pain, and access to pain management therapies. Understanding these variations is essential for developing targeted interventions and improving patient outcomes.

Key regions include:

- The United States
- Germany
- France
- Italy
- Spain
- The United Kingdom
- Japan
- India
These regions exhibit distinct epidemiological trends, reflecting the unique challenges and opportunities within their healthcare systems.

The epidemiology of opioid-induced constipation differs considerably across countries, influenced by factors such as opioid prescribing practices, healthcare systems, cultural views on pain management, the prevalence of chronic pain conditions, and access to preventive treatments. A 2023 survey in the American Journal of Gastroenterology found that in the United States, 1.7% of individuals experienced opioid-induced constipation (OIC) according to Rome IV criteria, while opioid-exacerbated constipation (OEC) was less prevalent at 0.4%.

Key Questions Answered
- How do variations in healthcare access and diagnostic practices influence the reported prevalence of opioid-induced constipation across different countries?
- What role do demographic factors such as age, gender, and comorbidities play in the epidemiology of opioid-induced constipation?
- How can changes in opioid prescribing guidelines impact future trends in opioid-induced constipation?
- What epidemiological methods are most effective in distinguishing opioid-induced constipation from other types of constipation?
- How does underreporting or patient reluctance to discuss gastrointestinal symptoms affect the accuracy of epidemiological data for opioid-induced constipation?
- What is the significance of real-world data and patient-reported outcomes in shaping the epidemiological profile of opioid-induced constipation?
- In what ways might cultural attitudes toward pain and medication influence the incidence and recognition of opioid-induced constipation?
- How do regional differences in opioid use for chronic pain management contribute to disparities in the global burden of opioid-induced constipation?
- What is the long-term impact of opioid-induced constipation on patient adherence to opioid therapy and overall quality of life?
- How can predictive modelling and longitudinal studies help in understanding the future burden and healthcare needs associated with opioid-induced constipation?

Scope of the Report
- The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of opioid-induced constipation based on several factors.
- The opioid-induced constipation epidemiology forecast report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India)
- The report helps to identify the patient population, the unmet needs of opioid-induced constipation are highlighted along with an assessment of the disease's risk and burden.
\";1 Preface